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Abstract
Impulse control disorders (ICDs) constitute a heterogeneous group of conditions linked
diagnostically by difficulties in resisting “the impulse, drive, or temptation to perform an act that is
harmful to the person or to others.” Specific ICDs share clinical, phenomenological and biological
features with obsessive-compulsive disorder (OCD) that have suggested that these disorders might
be categorized together. However, other data suggest significant differences between OCD and ICDs.
In this article, clinical, phenomenological and biological features of the formal ICDs are reviewed
and compared and contrasted with those of OCD. Available data indicate substantial differences
between ICDs and OCD that suggest independent categorizations. Existing research gaps are
identified and avenues for future research suggested.
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1. Introduction
In anticipation of the generation of the next editions of the Diagnostic and Statistical Manual
and the International Classification of Diseases, the American Psychiatric Association,
National Institutes of Health and World Health Organization have sponsored a series of
meetings entitled, “The Future of Psychiatric Diagnosis: Refining the Research Agenda.” The
conference focusing on Obsessive Compulsive Spectrum Disorders was convened on June 20–
22, 2006. Among the topics discussed were which disorders should be considered within the
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obsessive compulsive (OC) spectrum and whether disorders currently classified elsewhere
might be alternatively grouped in a manner supported by empirical data. Among the disorders
warranting consideration for grouping within an OC spectrum were the impulse control
disorders (ICDs), including pathological gambling (PG) and intermittent explosive disorder
(IED). Multiple domains representing potential endophenotypes were identified prior to the
meeting to foster exploration and discussion of this topic. These domains included
phenomenology, co-morbidity, course of illness, family history, genetics, brain circuitry, cross
species considerations, pharmacology, treatments and interventions, and cultural influences.
2.1. Impulse Control Disorders (ICDs): Current Categorization in DSM-IV-TR
ICDs are currently classified within the DSM-IV-TR in the category of “Impulse Control
Disorders Not Elsewhere Classified” (American Psychiatric Association Committee on
Nomenclature and Statistics, 2000). As the category name implies, other disorders
characterized by impaired impulse control (e.g., substance abuse and dependence, cluster B
personality disorders, and eating disorders) are categorized elsewhere in the DSM-IV-TR.
Included in the formal ICD category are IED, kleptomania, pyromania, PG, trichotillomania,
and ICDs not otherwise specified (NOS). Whereas formal criteria for other ICDs have been
proposed (e.g., for excessive, problematic or compulsive behavior in the domains of shopping
or buying, computer or internet use, sex, and skin picking (McElroy et al., 1994; Lejoyeaux et
al., 1996; Potenza and Hollander, 2002; Grant and Potenza, 2004; Koran et al., 2006; Liu and
Potenza, in press)), clinically significant behaviors in these areas would currently be diagnosed
as ICDs NOS. This article will focus on those ICDs with specific diagnostic criteria already
defined in the DSM since the ICDs without clearly defined diagnostic criteria have been less
well studied to date.
2.2. Common Features of ICDs: Relationship to OCD
As described in the DSM-IV-TR, the essential feature of ICDs is “the failure to resist an
impulse, drive, or temptation to perform an act that is harmful to the person or to others.” Each
ICD is characterized by a recurrent pattern of behavior that has this essential feature within a
specific domain. The repetitive engagement in these behaviors ultimately interferes with
functioning in other domains. In this respect, ICDs resemble OCD. That is, individuals with
OCD often report difficulties resisting the urge to engage in specific behaviors (e.g., cleaning,
ordering or other ritualistic behaviours) that interfere with functioning. However, this
resemblance is not unique to OCD. For example, individuals with drug addictions often report
difficulty in resisting the urge to use drugs. Perhaps for these reasons, two of the most common
conceptualizations of ICDs link them to an OC spectrum or to addictive disorders (Hollander
and Wong, 1995; Potenza et al., 2001). Although the categorizations of ICDs as OC spectrum
or addictive disorders are not mutually exclusive, they have important theoretical and clinical
implications given differences in the prevention and treatment strategies for these disorders
(Tamminga and Nestler, 2006). Heterogeneities in OCD and addictions and changes that occur
during the course of these disorders complicate comparisons across disorders, particularly as
investigations concurrently examining OCD, substance addictions, and ICDs are scarce.
ICDs and OCD have been conceptualized to lie along an impulsive/compulsive spectrum with
disorders with high harm avoidance like OCD positioned closer to the more compulsive end
and those with low harm avoidance like many ICDs positioned closer to the more impulsive
end (Hollander and Wong, 1995). Although data indicate that individuals with OCD score high
on measures of harm avoidance and those with ICDs like PG score high on measures of
impulsivity and related measures like novelty seeking (Potenza, in press), recent data suggest
a more complex relationship between impulsivity and compulsivity as they relate to OCD and
ICDs. For example, individuals with OCD as compared to control subjects demonstrated high
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levels of cognitive impulsiveness (Ettelt et al., 2007). An association between measures of
cognitive impulsiveness and aggressive obsessions and checking suggests that impulsiveness
may be particularly relevant to specific subgroups of individuals with OCD (Ettelt et al.,
2007). Another study of OCD, PG and control subjects found that the majority of both PG and
OCD subjects were characterized by high levels of both impulsivity and harm avoidance,
suggesting a more complex relationship between impulsivity and compulsivity than originally
proposed (Potenza, in press). More research is needed to examine the extent to which some of
these similarities across these disorders might explain similarities in specific clinical
phenomena; e.g., whether high levels of impulsiveness in PG and OCD account for high levels
of suicidality reported across these disorders (Ledgerwood et al., 2005; Torres et al., 2006).
Furthermore, the complex relationship between impulsivity may be influenced by different
factors in specific populations. For example, gender differences in the relationship between
measures of impulsivity and compulsivity have been reported in sample of high school students
(Li and Chen, 2007), and the extent to which these findings extend to groups with OCD and/
or ICDs has yet to be systematically investigated.
As described in the DSM-IV-TR (American Psychiatric Association Committee on
Nomenclature and Statistics, 2000), additional features common to ICDs are the feelings of
“tension or arousal before committing the act” and “pleasure, gratification or relief at the time
of committing the act.” There may or may not be feelings of regret, self-reproach or guilt
following the act. In multiple respects, the motivations and sensations preceding and relating
to the repetitive acts in ICDs and OCD are different. Among the most striking differences is
the ego-dystonic nature typically ascribed to the obsessions and compulsions in OCD as
compared with the ego-syntonic feelings typically associated with ICD behaviors such as
gambling (Stein and Lochner, 2006). The ego-syntonic nature of ICD behaviors is at least
superficially more similar to the experience of drug use behaviours in drug dependence.
Similarly, the variability in the degree of guilt or remorse following the ICD behavior is
reminiscent of the variability observed in individuals with drug addictions. However, the
motivational and emotional processes underlying engagement in and experiencing of the
repetitive behaviors in ICDs may change over time (Brewer and Potenza, in press; Chambers
et al., in press). For example, individuals with PG often report that while they initially gambled
to win money, later they became motivated simply by the experience of gambling itself (to be
“in action”). Whereas gambling urges early in the course of PG are typically pleasurable, over
time they often become less ego-syntonic as people more fully appreciate the negative
consequences of their gambling and struggle to refrain. Although these changes appear similar
to those reported during the course of the addictive process, they also resemble processes in
OCD. That is, as the urge to engage in an ICD behavior and the behavior itself become more
ego-dystonic, less driven by seeking of pleasure and more driven by a desire to reduce an
anxious or distressing state, the urge and behavior more closely resemble the phenomenological
features of obsessions and compulsions, respectively, in OCD. On the other hand, the ego-
dystonic quality of OCD symptoms may diminish over time (Rasmussen and Eisen, 1992).
2.3. Heterogeneity of ICDs: Unique Features
The behavioral domains covered by the current ICDs include anger management, stealing, fire
setting, gambling and hair-pulling. Since these domains are in many ways distinct and
disparate, a question arises as to whether the disorders should be grouped together. DSM-IV-
TR groups some other disorders characterized by excessive or interfering levels of engagement
separately according to the specific target behaviour (e.g., substance-related and eating
disorders). Data examining the extent to which ICDs warrant clustering are sparse. Until
recently, ICDs were typically omitted from large, epidemiological studies. Although recent
studies like the National Epidemiologic Survey on Alcoholism and Related Conditions
(NESARC) and the National Co-morbidity Survey Replication Study (NCS-R) included
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measures of specific ICDs like PG and IED (Petry et al., 2005; Kessler et al., 2006), the entire
group of disorders has not been assessed concurrently in a large, population-based sample.
Thus, the extent to which they form a cohesive group has not been directly examined, nor has
the extent to which they fit into an empirically supported structure of psychiatric disorders.
That is, data indicate that most psychiatric disorders can be categorized into internalizing or
externalizing clusters (Krueger, 1999; Kendler et al., 2003). Although ICDs often share with
externalizing disorders a disinhibited personality style or a lack of constraint (Slutske et al.,
2000; Slutske et al., 2001; Slutske et al., 2005), they also share features with internalizing
disorders such as major depression (Potenza et al., 2005; Potenza, 2007). Where OCD and
ICDs best fit within this structure warrants direct investigation. Whereas the disabling distress
and anxiety associated with OCD contributes to its current classification in DSM-IV-TR as an
anxiety disorder, it is categorized separately in the 10th edition of the International
Classification of Diseases (World Health Organization, 2003).
Existing studies suggest that the ICDs represent a heterogeneous group of disorders. Within a
clinical sample of subjects with OCD, pathological skin picking and nail biting were frequently
endorsed and other ICDs were relatively uncommon (Grant et al., 2006a). OCD subjects with
ICDs were more likely than those without OCD to acknowledge hoarding and symmetry
obsessions and hoarding and repeating rituals, suggesting a differential association of ICDs
with sub-groups of individuals with OCD (Grant et al., 2006a). Within a sample of probands
with or without OCD, excessive “grooming disorders” including trichotillomania and
pathological nail biting and skin picking were more common in the individuals with OCD
(Bienvenu et al., 2000). In contrast, other ICDs, including PG, pyromania and kleptomania,
were not more commonly identified in individuals with OCD versus those without the disorder.
This pattern extended to first-degree relatives, suggesting a heritable component to the overlap
between OCD and the grooming-related ICD behaviors. However, a study of individuals with
trichotillomania and their family members did not find a close link between OCD and
trichotillomania (Lenane et al., 1992). Methodological limitations, including relatively small
sample sizes, might be responsible in part for the heterogeneity in findings. Co-occurring ICDs
in OCD have been associated with an earlier age at onset of OCD, a more insidious appearance
of OC symptoms, a greater number and severity of OC symptoms, and a larger number of
therapeutic trials (du Toit et al., 2005; Fontenelle et al., 2005; Matsunaga et al., 2005; Grant
et al., 2006a).
An independent study found that OC spectrum disorders (including ICDs) in subjects with
OCD clustered into three groups: 1) a “reward deficiency” group that included trichotillomania,
PG, Tourette’s disorder, and hypersexual disorder; 2) an “impulsivity” group that included
kleptomania, IED, compulsive shopping and self-injurious behaviours; and 3) a “somatic”
group that included body dysmorphic disorder and hypochondriasis (Lochner et al., 2005). The
different clusters correlated with different clinical features of the OCD sample. Specifically,
cluster one associated with early age at onset of OCD and the presence of tics, cluster two with
female gender and childhood trauma, and cluster three with poor insight. These findings
highlight several important points. First, they suggest that ICDs cluster into distinct groups,
particularly within subjects with OCD. Second, specific groups of ICDs might be particularly
relevant to specific subsets of individuals with OCD. That is, data support the existence of
multiple sub-types of OCD with different clinical characteristics and treatment responses (e.g.,
tic versus non-tic-related and its relationship to early-onset and treatment refractoriness
(Leckman et al., 1994; McDougle et al., 1994; Denys et al., 2003; Leckman et al., 2003;
Rosario-Campos et al., 2005)). Factor analytic studies have suggested that particular OCD
symptom types (aggressive obsessions/checking; religious or sexual obsessions; symmetry/
ordering; contamination/cleaning; hoarding) may represent biologically distinct disorders
(Leckman et al., 2001), and positron emission tomography (PET) studies have found
differences in OCD subjects with different symptom clusters (Rauch et al., 1998). Specific
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ICDs (or clusters thereof) may be particularly relevant to specific sub-types of OCD; e.g., IED
and aggressive sub-types of OCD. More research is needed to examine the specific categorical
and dimensional features of OCD in relation to ICDs in order to clarify these relationships
(Lochner and Stein, 2006; Stein and Lochner, 2006).
2.4. Individual ICDs
Given individual differences between the ICDs, representative ICDs were selected for further
consideration according to the endophenotype domains identified for the OC spectrum
workgroup meeting: 1) phenomenology and epidemiology; 2) co-occurring disorders; 3)
family history and genetics; 4) neurobiology, including animal models and human studies; 5)
pharmacological and behavioural treatments and interventions; and 6) cultural considerations.
Some aspects relevant to OCD (e.g., important immune system contributions to OCD in a
subset of individuals (Snider and Swedo, 2004)) are not presently suspected in the etiology of
any of the formal ICDs and are not discussed below. Two ICDs, IED and PG, were selected
for consideration here because they: 1) have been identified as belonging to distinct categories
in OCD subjects in a data-driven cluster analysis (Lochner et al., 2005); and 2) have been most
thoroughly studied to date. This latter aspect is particularly relevant in that not all ICDs have
sufficient empirical data to address adequately all of the domains specified by the OC Spectrum
Disorders DSM V Research workgroup. The third cluster of OC spectrum disorders previously
identified (the somatic cluster including body dysmorphic disorder (Lochner et al., 2005)) will
not be addressed here because it does not include formal ICDs and is covered in a separate
article derived from the OC spectrum workgroup meeting. The findings from the cluster
analysis (Lochner et al., 2005) have limitations; e.g., they are obtained from a population with
OCD, thereby potentially introducing bias. However, similar studies have not been performed
in other populations. Consequently, these data seem the best available to guide decision-making
regarding which ICDs to cover most extensively here. Although it would be desirable to cover
each ICD in similar detail in the following sections, space limitations coupled with the intent
to cover adequately the domains identified prevent this.
3. Intermittent Explosive Disorder (IED)
3.1. Phenomenology and Epidemiology
Available data suggest that although there are similarities between IED and OCD, substantial
differences exist. IED is characterized by recurrent episodes of aggression that are out of
proportion to psychosocial stressors and/or provocation and are not better accounted for by
another mental disorder, by comorbid medical conditions, or by the physiological effects of a
drug or other substance with psychotropic properties (American Psychiatric Association
Committee on Nomenclature and Statistics, 2000). IED may be repetitive, intrusive, persistent
and recurrent like OCD, but is often episodic. Unlike compulsions in OCD, aggressive
outbursts in IED typically do not occur in response to an obsession. Agression is typically
unplanned and occurs without substantial forethought (Grant and Potenza, 2006a). Aggression
in IED differs from compulsions in OCD in that it may be gratifying and accompanied by
excitement rather than by anxiety reduction; however, like OCD compulsions, aggressive acts
can be perceived as distressing (McElroy et al., 1998).
Chart reviews of psychiatric inpatients (Monopolis and Lion, 1983) and clinical interviews
(Felthous et al., 1991) reported prevalence estimates of IED from 1% to 3% in psychiatric
settings (Olvera, 2002). A more recent study of adult psychiatric inpatients found that 6.4%
and 6.9% had current and lifetime IED, respectively (Grant et al., 2005). A separate study of
adolescent psychiatric inpatients found a larger proportion of subjects (12.7%) met criteria for
IED (Grant et al., in press). In both the adult and adolescent inpatient studies, diagnoses of IED
were only identified following active screening and interviewing. These findings suggest that
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IED, like other ICDs, often goes undiagnosed and thus is often not targeted for treatment.
Estimates of IED in community samples suggest that IED is common. For example, one
community study found a 11.1% lifetime prevalence and a 3.2% 1-month prevalence (Cocarro
et al., 2004). In the NCS-R study, lifetime and 12-month prevalence estimates of DSM-IV IED
were 7.3% and 3.9%, respectively (Kessler et al., 2006). Together, these studies suggest that
IED is more common than OCD.
In some respects, the clinical characteristics and course of IED resemble those of other
disorders characterized by impaired control (e.g., substance use disorders) more than those of
OCD. Unlike OCD, in which there is an approximately 1:1 male-to-female ratio (Robins and
Regier, 1991) or a slight female predominance (Mohammadi et al., 2004; Grabe et al., 2006),
IED is characterized by an approximately 2:1 male predominance (Grant and Potenza,
2006a; Kessler et al., 2006). Age at onset for DSM-IV IED peaks in the teenage years, is earlier
for men than women, and is earlier than for most disorders that frequently co-occur with IED
(see below), with the possible exception of phobic anxiety disorders (Kessler et al., 2006).
Similarly, many individuals (49%) report OCD symptom onset during childhood or
adolescence and a majority (75%) report onset prior to age 25 (Robins and Regier, 1991). In
IED, aggressive behaviors occur in nearly all decades of life beginning in the first decade,
peaking in the third decade, diminishing steadily after the fourth decade, and culminating in
little or no reported aggression by the eighth decade (Cocarro et al., 2004). Sociodemographic
correlates of lifetime IED include low educational level, being married, and having low family
income (Kessler et al., 2006). In contrast, OCD does not show a clear association with
educational level and married individuals are less likely to be afflicted (Robins and Regier,
1991).
3.2. Co-Occurring Disorders
Like other ICDs (Potenza, 2007), IED frequently co-occurs with other psychiatric disorders
including OCD. Initial findings were reported from clinical samples. One study reported OCD
in 22% of individuals with IED (McElroy et al., 1998). Estimates of IED in clinical samples
of subjects with OCD have ranged from about 2% to about 10% (du Toit et al., 2005; Fontenelle
et al., 2005). In the NCS-R, the vast majority (81.8%) of patients with lifetime broadly defined
IED met criteria for at least one other lifetime DSM-IV disorder (Kessler et al., 2006). A wide
range of psychiatric disorders was found in association with IED including mood, anxiety,
impulse control and substance use disorders (Kessler et al., 2006). Among individuals with
broadly defined IED, 4.4% met criteria for OCD. The odds ratio (OR) for broadly defined IED
in association with OCD was 2.5 (95% confidence interval (CI): 1.1–5.7). Within the broadly
defined group, there was no significant difference in the degree of association between the
narrowly defined IED and OCD (OR: 1.1; 95% CI: 0.2–6.9). In contrast, generalized anxiety
disorder, all ICDs and many substance use disorders showed significantly elevated ORs for
both broadly and narrowly defined IED, suggesting a particularly close relationship between
these disorders and both less and more severe forms of IED (Kessler et al., 2006).
3.3. Family History and Genetics
Although studies suggest that impulsive and aggressive behaviours demonstrate familial
transmission (Halperin et al., 2003; Kreek et al., 2005), few genetic or family history studies
have been performed in individuals with IED. Several lines of research have identified familial
sociopathy and aggression as salient risk factors for the persistence of childhood aggression
into adolescence and adulthood (Cadoret et al., 1995; Frick et al., 1990). A familial pattern of
aggressive behaviors has been associated with central serotonin function (see neurobiology
below) (Halperin et al., 2003). The family history of individuals with IED is characterized by
high rates of mood, substance use and other impulse control disorders (McElroy et al., 1998).
A genetic linkage study found an association between an allelic variant of the serotonin (5HT)
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1B receptor gene and alcoholism in aggressive/impulsive individuals who met criteria either
for antisocial personality disorder or IED (Lappalainen et al., 1998). In contrast, the 5HT 1B
receptor has not been implicated in genetic studies of OCD, although several other 5HT-related
genes (e.g., those encoding the 5HT 1D and 5HT 2A receptors and the 5HT transporter), have
been implicated in some but not all studies of OCD (Hemmings and Stein, 2006).
3.4. Neurobiology: Animal Models and Human Studies
Many neurotransmitter systems and brain regions contribute to impulsive aggression. Animal
models have implicated numerous biological systems and neurotransmitters including those
involving testosterone, gamma-amino butyric acid, nitric oxide, monoamine oxidase,
glutamate, dopamine and serotonin (Olivier and Young, 2002; Korff and Harvey, 2006). Within
these systems, specific components seem particularly salient. For example, robust data
implicate the 5HT 1B receptor in impulsive aggression in mice; knockout mice lacking the
receptor show marked physical aggression (Saudou et al., 1994). These findings are consistent
with human studies implicating the receptor in impulsive aggressive alcoholism (Lappalainen
et al., 1998). Although some of the same systems (e.g., 5HT, dopamine) are relevant to both
IED and OCD, they seem involved in different ways. For example, disruption of the genes
encoding the 5HT 2C receptor and the dopamine transporter generate stereotypic behaviours
resembling OCD (Korff and Harvey, 2006), as compared with the 5HT 1B receptor
manipulation more relevant to IED. Genetic variations in commonly occurring 5HT-related
gene variants (e.g., of the 5HT transporter) influence 5HT measures associated with impulsive
aggression (Mannelli et al., 2006).
Few studies have examined the neurobiology of IED in humans, and those available have not
consistently identified between-group differences. For example, a magnetic resonance
spectroscopy study that identified differences in adolescent bipolar and control subjects in
myoinositol measures found no differences between adolescents with and without IED
(Davanzo et al., 2003). Although few studies have been performed in individuals with IED,
many have investigated individuals with impulsive aggression. Multiple biological systems,
including those involving opiates, vasopressin, testosterone, catecholamines (norepinephrine,
dopamine), and 5HT, have been identified as contributing to human aggression (Coccaro and
Siever, 2002). Amongst the most widely replicated findings is that of low levels of central
measures of 5HT (particularly of the 5HT metabolite 5-hydroxy indole acetic acid) in impulsive
aggressive individuals (Coccaro and Siever, 2002; Williams and Potenza, in press). Although
5HT systems have been implicated in OCD, the nature of the involvement differs, as judged
by the results of pharmacological challenge studies. Administration of the serotonergic drugs
meta-chlorophenylpiperazine (m-CPP, a 5HT1 and 5HT2 receptor agonist (Potenza and
Hollander, 2002)) and fenfluramine (a drug inducing 5HT release and having post-synaptic
5HT action (Curzon and Gibson, 1999)) is associated with an exacerbation of OC symptoms
and enhanced prolactin release in subjects with OCD (Hollander et al., 1991; Monteleone et
al., 1997; Gross-Isseroff et al., 2004). However, groups of children and adults characterized
by impulsive aggression exhibit a blunted prolactin response to m-CPP and fenfluramine
(Cocarro et al., 1997; Halperin et al., 2003; New et al., 2004b; Patkar et al., 2006). These
findings are consistent with those from primates, in which an inverse relationship between
aggression and serotonergic activity has been reported (Tiefenbacher et al., 2003)
Brain imaging studies have yielded insight into the pathophysiology of impulsive aggression
in humans. Consistent with a role for the ventromedial prefrontal cortex (vmPFC, a region
including the medial orbital frontal cortex (Bechara, 2003)) in decision-making and social and
moral judgments (Damasio, 1994; Anderson et al., 1999; Bechara, 2003), individuals with
impulsive aggression show relatively diminished activation of vmPFC. For example, among
individuals with depression, those with anger attacks showed an inverse correlation between
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regional cerebral blood flow in the left vmPFC and left amygdala during anger induction,
whereas subjects without anger attacks did not (Dougherty et al., 2004). Aspects of vmPFC
function as related to impulsive aggression appear linked to 5HT function. Individuals with
impulsive aggression as compared to those without show blunted hemodynamic responses to
the serotonergic drugs fenfluramine (Siever et al., 1999) and m-CPP (New et al., 2002).
Individuals with impulsive aggression also show diminished 5HT availability in the anterior
cingulate cortex, including within the ventral portion included in the vmPFC (Frankle et al.,
2005). The 5HT reuptake inhibitor (SRI) fluoxetine increases metabolism within orbitofrontal
cortex (New et al., 2004a). Although orbitofrontal cortical function has been implicated in
OCD, the nature of its involvement differs from that in impulsive aggression. Specifically, in
apparent contrast to the diminished vmPFC activity associated with impulsive aggression,
increased activation of cortical-striato-thalamo-cortical circuitry, including orbitofrontal
regions involving vmPFC, has been repeatedly implicated in OCD (Korff and Harvey, 2006;
Mataix-Cols and van den Heuvel, 2006). However, specific subgroups of individuals with OCD
show differential activation of this circuitry. For example, during an fMRI symptom
provocation study, individuals with washing OCD showed strong activation of vmPFC and
caudate, those with checking OCD showed strong activation of putamen/globus pallidus,
thalamus, and dorsal cortical areas, and those with hoarding showed OCD strong activation of
precentral gyrus and orbitofrontal cortex (Mataix-Cols et al., 2004).
3.5. Pharmacological and behavioural treatments and interventions
Relatively few clinical trials have investigated the efficacy and tolerability of drugs in the
treatment of IED. Drugs that block serotonin transport (both relatively selective and non-
selective SRIs like sertraline and venlafaxine, respectively) have been reported in case reports
to be helpful in individuals with IED (McElroy et al., 1998; Feder, 1999). Although this finding
may suggest similarities to the use of SRIs in treating OCD, the doses employed were often
lower than those typically used in OCD (Denys, 2006). For example, in one case series
involving IED subjects, sertraline was dosed at 50–100 mg/day (Feder, 1999) rather then the
doses approaching 200 mg/day often used for OCD. A role for SRIs in the treatment of IED is
consistent with their efficacy in targeting impulsive aggression (Coccaro and Kavoussi,
1997; Reist et al., 2003). Mood stabilizing drugs like lithium and valproic acid have been
reported helpful in open-label IED treatment studies (McElroy et al., 1998), consistent with
findings from some but not all studies of these and other mood stabilizers (carbamazepine,
phenytoin) in targeting impulsive aggression (Olvera, 2002; Dell'Osso et al., 2006; Grant and
Potenza, 2006a). However, lithium lacks efficacy as an augmenting agent in the treatment of
OCD (McDougle et al., 1991), although some antipsychotic drugs (e.g., olanzapine,
risperidone) with mood stabilizing properties have demonstrated efficacy in augmenting SRI
response in refractory OCD (Denys, 2006). Some antipsychotic drugs have also been effective
in treating aggression in controlled studies (Findling et al., 2001; Buitelaar et al., 2001). Alpha-
adrenergic agonists and beta-adrenergic antagonists have each shown some promise in
targeting impulsive aggression (Olvera, 2002; Dell'Osso et al., 2006; Grant and Potenza,
2006a), whereas no role for these drugs has been demonstrated in the treatment of OCD (Denys,
2006). Taken together, although the data for IED are limited, existing information suggests
that the similarities in the pharmacological treatments of IED and OCD are outweighed by
substantial differences.
Data from psychotherapy trials for individuals with IED are limited, with suggestions that
insight-oriented psychotherapy and behavioral therapy might be helpful for some individuals
(Grant and Potenza, 2006a). Limited studies involving small numbers of subjects have not
found significant improvement related to group, couples or family therapies (McElroy et al.,
1998). With respect to aggressive behaviours, controlled studies of behavioral interventions
including CBT, group therapy, family therapy and social skill training report some
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effectiveness for aggressive patients (Alpert and Spilman, 1997). These treatments differ from
the exposure and response prevention methods that are effective in the treatment of OCD
(Neziroglu et al., 2006). Thus, like the pharmacotherapy data, the behavioural therapy findings
suggest significant differences between IED and OCD.
3.6. Cultural Considerations
Cultural attitudes towards aggressive behaviours warrant consideration in IED, although little
systematic research has been performed with respect to the influence of cultural factors. One
form of aggression, amok episodes, are characterized by acute, unrestrained violence, typically
associated with amnesia, and traditionally seen only in southeastern Asian countries (American
Psychiatric Association Committee on Nomenclature and Statistics, 2000). The extent to which
IED resembles amok episodes or perceptions thereof warrants examination. Although OCD
occurs across racial/ethnic groups and geographic locations (Karno et al., 1988; Mohammadi
et al., 2004), cultural differences are important to consider since cultural norms relating to a
range of ritualistic behaviours may differ (American Psychiatric Association Committee on
Nomenclature and Statistics, 2000). Although cultural considerations exist for both IED and
OCD, the nature of the associations between specific cultural factors and the two disorders
appears to differ.
4. Pathological Gambling (PG)
4.1. Phenomenology and Epidemiology
PG has been hypothesized to represent both an OC-spectrum disorder and an addiction without
a drug, and data exist to support each categorization (Hollander and Wong, 1995; Potenza et
al., 2001). While these categorizations are not mutually exclusive, they have important
theoretical and clinical implications (Tamminga and Nestler, 2006). Repetitive, intrusive
thoughts about gambling in PG share features with obsessions in OCD. Like OCD, PG is
characterized by repetitive behaviours. In PG, gambling and gambling-related behaviors (e.g.,
handicapping, getting money to gamble, etc) are performed repeatedly (Potenza et al., 2001).
As with OCD, the behaviors typically interfere significantly with major areas of functioning
(American Psychiatric Association Committee on Nomenclature and Statistics, 2000). In
contrast to the ego-dystonic behaviors related to OCD, gambling in PG is typically initially
ego-syntonic or hedonic in nature, although over time the pleasure derived from gambling may
diminish. In this respect, the gambling in PG may be similar to drug use in drug dependence,
and this and other phenomenological similarities have suggested that PG may represent a
“behavioral addiction” (Holden, 2001; Petry, 2006; Potenza, 2006). A telescoping
phenomenon has been reported for PG and in drug and alcohol dependence in which women
on average initially engage in disorder-related behavior at a later age but progress more quickly
(“telescope”) than do men to problematic levels (Potenza et al., 2001; Tavares et al., 2001).
The ratio of men:women with PG (about 2:1) also resembles that in drug and alcohol
dependence more than the ratio seen in OCD (about 1:1) (Potenza et al., 2001; Petry, 2006;
Potenza, 2006). The existing data on the clinical courses of PG and substance dependance also
suggest similarities, with neglible rates in childhood, high rates in adolescence and young
adulthood and lower rates in older adults (Chambers and Potenza, 2003; Potenza, 2006). These
patterns differ from those observed in OCD. For example, in OCD onset during childhood is
relatively common (American Psychiatric Association Committee on Nomenclature and
Statistics, 2000). Many inclusionary diagnostic criteria for PG are more reflective of those for
substance dependence, including aspects of tolerance, withdrawal, repeated unsuccessful
attempts to cut back or quit, and interference in major areas of life functioning. Personality
measures suggest that individuals with PG, like those with substance dependence, are impulsive
and sensation-seeking (Blaszczynski et al., 1997; Potenza et al., 2003b) whereas those with
OCD are more harm-avoidant (Hollander and Wong, 1995; Anholt et al., 2004). Thus, although
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there are phenomenological similarities between PG and OCD, those between PG and
substance dependence appear more robust.
4.2. Co-Occurring Disorders
Studies of clinical samples indicate high rates of co-occurrence between PG and a broad range
of internalizing and externalizing disorders, including both Axis I and Axis II conditions
(Crockford and el-Guebaly, 1998; Potenza, 2007). Data from community samples also indicate
high rates of co-occurring disorders. For example, data from the St. Louis Epidemiologic
Catchment Area (ECA) study found elevated odds ratios between problem/pathological
gambling and major depression, anxiety disorders (phobias, somatization), drug use disorders
(nicotine dependence and alcohol abuse/dependence), psychotic disorders, and antisocial
personality disorder (Cunningham-Williams et al., 1998). A non-elevated odds ratio of 0.6 was
observed between problem/pathological gambling and OCD (Cunningham-Williams et al.,
1998). Other large community samples (e.g., the sample of male twins in the Vietnam Era Twin
(VET) registry) have also shown elevated associations between PG and mood, anxiety,
substance use, and antisocial personality disorders (Potenza et al., 2005). More recently, data
from the NESARC indicated elevated odds ratios for PG in association with numerous axis I
and axis II disorders including alcohol, nicotine and other drug dependence, mood disorders
(including manic and depressive episodes), anxiety disorders (including panic, phobic and
generalized anxiety), and personality disorders (including avoidant, dependent, obsessive-
compulsive, paranoid, schizoid, histrionic, and antisocial) (Petry et al., 2005). In neither the
NESARC nor the VET samples were diagnostic assessments of OCD obtained. Thus, existing
community-based data suggest a stronger connection between PG and a broad range of other
psychiatric disorders than exists between PG and OCD.
4.3. Family History and Genetics
Twin studies indicate that PG has a high rate of heritability. A study of 3,359 male twin pairs
concluded that heredity explained from 35% to 54% of the liability for PG (Eisen et al.,
1998; Shah et al., 2005). These findings are consistent with a smaller family history study in
which estimates of PG in relatives of probands with PG were 9%, substantially higher than the
1% rate typically observed in the general population (Black et al., 2003). Consistent with the
existing data on co-occurring disorders, family history studies do not indicate high rates of PG
among family members of probands with OCD (Hollander et al., 1997; Bienvenu et al.,
2000). Also consistent with patterns of co-occurring disorders seen in population-based
samples (Cunningham-Williams et al., 1998; Petry et al., 2005), data from the VET registry
indicate significant genetic and environmental contributions to PG and to its co-occurrence
with alcohol dependence (Slutske et al., 2000) and antisocial behaviors (Slutske et al., 2001).
In compariosn, the overlap between PG and major depression is predominantly attributable to
shared genetic factors (Potenza et al., 2005). Similar studies probing the relationship between
PG and OCD have not been reported.
Candidate gene studies have suggested that multiple commonly occurring allelic variants
contribute to PG (Ibanez et al., 2003; Shah et al., 2004). The Taq-A1 polymorphism of the
gene encoding the D2 dopamine receptor has been associated with PG, attention deficit
hyperactivity disorder, Tourette’s syndrome, alcohol and drug abuse/dependence, anti-social
behaviors, and poor inhibitory control (Blum et al., 1996; Comings, 1998; Ponce et al., 2003;
Rodriguez-Jimenez et al., 2006). Other allelic variants including those in genes coding for the
D1 dopamine receptor, monoamine oxidase A enzyme, and the 5HT transporter, among others,
have been implicated in PG (Perez de Castro et al., 1997; Comings, 1998; Perez de Castro et
al., 1999; Comings et al., 2001; Ibanez et al., 2003; Shah et al., 2004; Williams and Potenza,
in press). Although some of the same allelic variants (e.g., variants of the 5HT transporter gene)
have been implicated in OCD and PG, the nature of the association has differed, with the long
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allele found in association with OCD and the short allele found in association with PG (Ibanez
et al., 2003; Hemmings and Stein, 2006). Moreover, the findings in OCD have been
inconsistent, with several studies implicating the allele and others not (Hemmings and Stein,
2006). Numerous limitations exist in the candidate gene studies performed to date in PG. For
example, some studies have not included diagnostic assessments or considered differences in
racial/ethnic compositions between groups. As a result, these studies should be regarded as
preliminary, with more work needed to identify the specific genetic contributions to PG and
how they compare and contrast with those underlying OCD.
4.4. Neurobiology: Animal Models and Human Studies
Although animal models of PG per se have not been established, frontostriatal circuitry has
been implicated across species in tasks involving impulsive choice (Jentsch and Taylor,
1999; Schultz et al., 2000; Everitt and Robbins, 2005). This circuitry has also been implicated
in human studies of PG (Potenza, 2001; Potenza, 2006; Williams and Potenza, in press). Brain
imaging studies of individuals with PG have implicated vmPFC during gambling urges
(Potenza et al., 2003b), cognitive control (Potenza et al., 2003a), and simulated gambling
(Reuter et al., 2005). In non-PG subjects, this brain region is involved in cognitive processes
relevant to gambling, including reward processing (Knutson et al., 2001; McClure et al.,
2004) and risk-reward decision-making (Bechara et al., 1998; Bechara et al., 1999; Bechara,
2003). Studies of performance on neurocognitive tasks targeting these processes have revealed
differences between PG and control comparison subjects (Petry and Casarella, 1999; Petry,
2001; Cavedini et al., 2002a). Differences between PG and control subjects in decision-making
task performance have been found (Cavedini et al., 2002a) and these differences are similar to
those between OCD and control subjects (Cavedini et al., 2002b) and those between drug
dependent and control subjects (Bechara, 2003). However, the brain activations underlying
these between-subject-group differences on decision-making tasks have not been directly
examined. Given that increased activation of frontostriatal circuitry has been repeatedly
observed in OCD (Mataix-Cols and van den Heuvel, 2006) and diminished activation seen in
PG (Reuter et al., 2005; Potenza, 2006), concurrent investigation of PG, OCD, drug dependent
and control subjects on the neural correlates of cognitive processes relevant to these subject
groups is needed.
Pharmacological challenge studies have implicated multiple neurotransmitter systems in PG,
including 5HT, dopamine, norepinephrine opioid and other systems (Potenza, 2001; Potenza
and Hollander, 2002; Chambers and Potenza, 2003). Many of these systems are implicated in
other psychiatric disorders including OCD, in which data indicating involvement of 5HT and
dopamine systems are well-substantiated (Pauls et al., 2002). However, data suggest
differences in the nature of the involvement of these systems in PG and OCD. Studies in OCD
subjects of pro-serotonergic agents like m-CPP indicate that a substantial proportion (about
50%) report a transient worsening of symptoms following drug challenge (Pauls et al., 2002).
In contrast, individuals with PG are more likely to report a euphoric or “high” response to pro-
serotonergic agents (Potenza and Hollander, 2002). These findings not only complement brain
imaging findings in which similar paradigms suggest between-group differerences of opposite
valences in OCD and PG (Potenza et al., 2003b), but also suggest that specific components of
impulsivity (e.g., those related to euphoria in relationship to disinhibition) may be linked to
specific components of the 5HT systems.
4.5. Pharmacological and behavioural treatments and interventions
Over the past decade our understanding of safe and effective treatments for PG has advanced
considerably (Grant and Potenza, 2004; Grant and Potenza, 2007; Brewer et al., in press). Both
similarities and differences are evident with respect to pharmacological treatments for PG and
OCD. First-line pharmacotherapy for OCD involves the use of SRIs, drugs that have been
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shown in multiple placebo-controlled, randomized clinical trials (RCTs) to be effective (Denys,
2006). The role for SRIs in the treatment of PG is less clear. While several RCTs have found
SRIs like fluvoxamine and paroxetine to be superior to placebo in the treatment of PG
(Hollander et al., 2000; Kim et al., 2002), others have not found a statistically signifcant effect
(Blanco et al., 2002; Grant et al., 2003). These findings suggest that there exist significant
individual factors related to treatment outcome in groups of individuals with PG. Considering
co-occurring disorders might be one method for guiding pharmacotherapies (Hollander et al.,
2004; Potenza, 2007). For example, a recent study of escitalopram in the treatment of PG and
co-occurring anxiety found concurrent reduction in anxiety and gambling symptoms during
open-label treatment (Grant and Potenza, 2006b). In subjects receiving active drug during the
double-blind discontinuation phase, clinical response was maintained; in contrast, placebo
treatment was associated with symptom worsening (Grant and Potenza, 2006b). Emerging data
suggest roles for glutamatergic therapies in the treatment of both OCD and PG (Denys,
2006; Grant, 2006). However, the results from these and most other pharmacotherapy trials of
PG should be considered cautiously given such limitations as small sample sizes and short-
term treatment durations. Particular caution is warranted with respect to open-label findings
given high placebo response rates observed in PG studies (Grant and Potenza, 2004).
Results of other pharmacotherapy trials suggest differences between PG and OCD. For
example, opioid antagonists like naltrexone and nalmefene have been found to be superior to
placebo in the treatment of PG (Kim et al., 2000; Grant et al., 2006b). In contrast, the opioid
antagonist naloxone has been associated with symptom exacerbation with OCD (Insel and
Pickar, 1983; Keuler et al., 1996). Whereas mood stabilizers like lithium may be helpful in
groups of subjects with PG (Hollander et al., 2005), their efficacy in OCD seems questionable
(McDougle et al., 1991). Whereas antipsychotic drugs that antagonize D2 dopamine receptors
(e.g., haloperidol, risperidone and olanzapine) have shown efficacy as augmenting agents in
OCD (Denys, 2006), existing data do not support a role for these drugs in the treatment of PG
(Grant and Potenza, 2004).
Data suggest that behavioral therapies have important roles in the treatment of PG and OCD.
However, the specific behavioral interventions differ. In PG, the 12-step program Gamblers
Anonymous (GA) is arguably the most widely used intervention and existing data suggest that
those who attend fare better than those who do not (Petry, 2005; Brewer et al., in press). The
extent to which this represents a true treatment effect or reflects selection bias (i.e., those
motivated to stay in GA are also motivated not to gamble) warrants more investigation. GA,
an intervention with limited economic burden, is modelled after Alcoholics Anonymous. No
similarly organized 12-step program is established for or believed to be helpful for individuals
with OCD. Behavioral therapies helpful for individuals with PG include motivational
enhancement or interviewing and cognitive behavioral therapy (Sylvain et al., 1997; Hodgins
et al., 2001; Petry et al., 2006; Grant and Potenza, 2007; Brewer et al., in press). These
approaches tend to be modelled after ones with demonstrated efficacy in the treatment of drug
addiction (Miller, 1995; Carroll et al., 1998) rather than the exposure/response prevention
strategies that are effective for treating OCD (Hohagen et al., 1998; Neziroglu et al., 2006).
4.6. Cultural Considerations
Both PG and OCD are present across cultures. Cultural differences relating to social
acceptability and availability of legalized gambling might influence rates of PG (Shaffer et al.,
1999). Like with OCD, largely similar estimates of PG prevalence have been observed in
studies around the world (Cunningham-Williams and Cottler, 2001; Abbott et al., 2004).
Nonetheless, certain populations (e.g., southeast Asian immigrants (Petry, 2003)) have
particularly high rates of gambling problems. The precise reasons for these findings require
additional investigation. Environmental contributions that might differ across cultures and
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contribute to PG are likely to differ from those contributing to OCD, but more research is
needed to investigate this notion directly.
5. Conclusions, Existing Limitations and Future Directions
While ICDs resemble OCD in some domains, existing data suggest substantial differences
between ICDs and OCD. Although progress has been made over the last decade in
understanding ICDs and OCD, existing data are often limited and include methodological
concerns that are sometimes severe and complicate interpretation and comparisons across
subject groups. Methodological limitations include ascertainment bias affecting the samples
evaluated, small study samples, error-prone methods of data-gathering (e.g., gathering family
history from probands without confirmatory interviews of family members), differing methods
of establishing diagnoses (e.g., structured versus unstructured interviews) and differing
methods of examining biological characteristics (e.g., different methods of brain imaging). For
many data domains (e.g., genetics, neurobiology and immune function), there exist little or no
data for many of the ICDs and only limited data for OCD. The group of ICDs as a whole
remains understudied and specific ICDs (e.g., pyromania and kleptomania) receive particularly
little attention from the research and clinical communities. Other proposed ICDs (including
compulsive buying or shopping, compulsive computer use or problematic internet use,
compulsive sexual behavior, compulsive skin-picking/nail-biting) need further examination.
For these ICDs, it is recommended that diagnostic criteria be derived for DSM-V from
examinations of large samples of clinical cases or of subjects ascertained through random-
sample community surveys (Koran et al., 2006; Aboujade et al., 2006). ICDs, when present,
often go unrecognized within clinical settings (Grant et al., 2005; Grant et al., in press), and
this under-recognition is associated with sub-optimal treatment outcomes in multiple domains
(Potenza, 2007). Thus, increased efforts to identify ICDs are needed to enhance clinical care
(Chamberlain et al., 2007).
Numerous gaps exist in our understanding of ICDs and their relationships with OCD and other
psychiatric disorders. Additional research is needed to obtain evidence for clustering individual
ICDs together or to support alternate categorizations (Lochner et al., 2005). From a broader
perspective, it is important to examine the relationships between non-ICD psychiatric disorders
and individual ICDs or empirically derived groups thereof. These investigations will have not
only theoretical implications for grouping the disorders, but also direct clinical relevance given
the high rates of co-occurring disorders observed in individuals with ICDs (Potenza, 2007).
As ICDs often have elements consistent with relationships with several psychiatric disorders
(e.g., addictions and OCD (Grant et al., 2007)), investigations of dimensional as well as
categorical measures of psychiatric sympotomatology are needed (Saxena et al., 2005; Muthen,
2006). Within each ICD, identification of individual characteristics that differentiate subgroups
of individuals with unique treatment needs is important. Identification of relevant
endophenotypes that can facilitate prevention and treatment advances is needed and should
include an understanding of specific environmental, genetic and interactive influences
(Gottesman and Gould, 2003; Kreek et al., 2005). The potential clinical utilities of these specific
individual differences or endophenotypes in targeting behavioral and pharmacological
interventions and for identifying high- versus low-risk individuals requires direct examination.
Amongst the most salient needs is an improved understanding of the pathophysiologies of
ICDs. Additional large-scale molecular genetic and brain imaging studies are needed to better
understand the biological underpinnings of the disorders and to translate this information into
clinical advances in prevention and treatment.
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